Skip to content

PROPANC BIOPHARMA, INC.: 10-Q filed 2020-05-15

What PROPANC BIOPHARMA, INC. reported in its quarterly report filed 2020-05-15 (fiscal Q3 2020): 32 published measures, 85 facts as tagged in accession 0001493152-20-009146.

This filing

Form
10-Q (quarterly report)
Filed
2020-05-15
Fiscal period
fiscal Q3 2020
Accession
0001493152-20-009146 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-03-3163,938USD
At 2019-06-30101,652USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-03-314,910,845USD
At 2019-06-304,402,888USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-03-31-4,846,908USD
At 2019-12-31-5,671,985USD
At 2019-09-30-4,541,732USD
At 2019-06-30-4,301,236USD
At 2019-03-31-3,413,022USD
At 2018-12-31-3,904,036USD
At 2018-09-30-5,558,044USD
At 2018-06-30-6,751,920USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,585,662USD91
2019-07-01 to 2020-03-31-5,944,711USD275
2019-10-01 to 2019-12-31-1,867,109USD92
2019-07-01 to 2019-09-30-1,491,940USD92
2019-01-01 to 2019-03-31-581,856USD90
2018-07-01 to 2019-03-31-4,156,830USD274
2018-10-01 to 2018-12-31-1,450,038USD92
2018-07-01 to 2018-09-30-2,124,936USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-07-01 to 2020-03-31-1,349,931USD275
2018-07-01 to 2019-03-31-1,793,805USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-07-01 to 2019-03-312,874USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-07-01 to 2020-03-311,465,250USD275
2018-07-01 to 2019-03-311,920,159USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-07-01 to 2019-03-31-2,874USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-03-31-56,985,758USD
At 2019-06-30-51,041,047USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-26,317USD91
2019-07-01 to 2020-03-31-135,068USD275
2019-01-01 to 2019-03-31726USD90
2018-07-01 to 2019-03-31-116,244USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-03-315,648USD
At 2019-06-308,417USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-07-01 to 2020-03-31225,312USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-607,168USD91
2019-07-01 to 2020-03-31-2,900,186USD275
2019-01-01 to 2019-03-31-571,725USD90
2018-07-01 to 2019-03-31-1,778,416USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-03-3131,500USD
At 2019-06-3091,132USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-01-01 to 2020-03-31384,804USD91
2019-07-01 to 2020-03-311,506,111USD275
2019-01-01 to 2019-03-31189,809USD90
2018-07-01 to 2019-03-311,309,336USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-03-314,890,800USD
At 2019-06-304,402,888USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-03-31607,168USD91
2019-07-01 to 2020-03-312,900,186USD275
2019-01-01 to 2019-03-31571,725USD90
2018-07-01 to 2019-03-311,778,416USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-03-3157,484USD91
2019-07-01 to 2020-03-31122,893USD275
2019-01-01 to 2019-03-3152,655USD90
2018-07-01 to 2019-03-31203,625USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-03-3118,481,410shares
At 2019-06-30967,993shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-03-3148,879,086USD
At 2019-06-3045,713,322USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-03-313,282,760USD
At 2019-06-301,066,998USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-03-3124,959USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-03-3127,335USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2020-03-312,711,173USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-06-3083,299USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-304,093USD91
2019-07-01 to 2020-03-31-3,728,949USD275
2019-01-01 to 2019-03-31-697,423USD90
2018-07-01 to 2019-03-31-3,637,902USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-31542,093USD91
2019-07-01 to 2020-03-312,751,478USD275
2019-01-01 to 2019-03-31511,822USD90
2018-07-01 to 2019-03-311,553,016USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-07-01 to 2020-03-311,859USD275
2018-07-01 to 2019-03-311,661USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,004,811USD91
2019-07-01 to 2020-03-31-3,179,593USD275
2019-01-01 to 2019-03-31-9,405USD90
2018-07-01 to 2019-03-31-2,494,658USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-07-01 to 2020-03-316,337USD275
2018-07-01 to 2019-03-31100,719USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2019-07-18 to 2019-07-1939,800USD2
2018-07-01 to 2019-03-311,031,979USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-07-01 to 2020-03-31207,071USD275
2018-07-01 to 2019-03-31-245,642USD274

Inspect the source

Entity
PROPANC BIOPHARMA, INC. / CIK 0001517681
Captured
2026-09-20T09:14:07.933Z
SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))